Zilucoplan Sodium Patent Expiration
Zilucoplan Sodium is Used for treating generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive by subcutaneously administering the C5 complement inhibitor zilucoplan. It was first introduced by Ucb Inc
Zilucoplan Sodium Patents
Given below is the list of patents protecting Zilucoplan Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zilbrysq | US10106579 | Modulation of complement activity | Jun 12, 2035 | Ucb Inc |
| Zilbrysq | US10208089 | Modulation of complement activity | Jun 12, 2035 | Ucb Inc |
| Zilbrysq | US10435438 | Modulation of complement activity | Jun 12, 2035 | Ucb Inc |
| Zilbrysq | US10562934 | Modulation of complement activity | Jun 12, 2035 | Ucb Inc |
| Zilbrysq | US10835574 | Modulators of complement activity | Jun 12, 2035 | Ucb Inc |
| Zilbrysq | US11014965 | Modulation of complement activity | Jun 12, 2035 | Ucb Inc |
| Zilbrysq | US11535650 | Modulation of complement activity | Jun 12, 2035 | Ucb Inc |
| Zilbrysq | US11752190 | Modulators of complement activity | Jun 12, 2035 | Ucb Inc |
| Zilbrysq | US11965040 | Modulation of complement activity | Jun 12, 2035 | Ucb Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zilucoplan Sodium's patents.
Latest Legal Activities on Zilucoplan Sodium's Patents
Given below is the list recent legal activities going on the following patents of Zilucoplan Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 22 May, 2024 | US10562934 |
| Second letter to regulating agency to determine regulatory review period | 22 May, 2024 | US10106579 |
| Second letter to regulating agency to determine regulatory review period | 22 May, 2024 | US10208089 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 May, 2024 | US10835574 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US10208089 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US10106579 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US10562934 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US10835574 |
| Initial letter Re: PTE Application to regulating agency | 11 Jan, 2024 | US10106579 |
| Initial letter Re: PTE Application to regulating agency | 11 Jan, 2024 | US10208089 |
Zilucoplan Sodium's Family Patents
